Sign In
29 May 2009 16:39
ο»Ώ
NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY OR CONNECTED PERSONS
VERNALIS PLCΒ (the "Company")
WINNERSH, U.KΒ 29Β May 2009Β Vernalis plc (LSE: VER) announces that in accordance with DTR 3.1.2R and following a resolution by the Board of Vernalis plc passed in accordance with share scheme arrangements approved by shareholders, the following options over new ordinary shares ofΒ 20Β penceΒ each in the Company were today granted:
|
PDMR |
No of shares under option |
Exercise Price |
% of Issued Share Capital |
|
Dr M Wood |
131,808 |
66Β pence |
0.23Β % |
|
Dr S Pawsey |
113,636 |
66Β pence |
0.20Β % |
|
Dr N Clark |
97,335 |
66 pence |
0.17 % |
The options are exercisable between three and ten years following grant provided that the performance conditionsΒ of the option scheme are met.Β
Enquiries:
Vernalis plc +44 (0) 118 977 3133
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer
Β
Brunswick Group +44 (0) 20 7404 5959
Jon Coles
Justine McIlroy
About Vernalis:
Vernalis is a development stage pharmaceutical company developing a pipeline of clinical and early stage programmes. The company currently has seven product candidates in clinical development (two of which are partnered) and two programmes in pre-clinical trials (one with a partner) and other competitive research programmes. Our collaborations are with leading, global pharmaceutical companies including Biogen Idec, Novartis, Servier, Chiesi, Menarini and Endo.
For further information about Vernalis, please visit www.vernalis.com.
Follow the stocks
